Xcout IntelRestore Vision
Restore Vision Inc. is a Japanese startup headquartered in Tokyo that aims to develop visual restoration gene therapies.
Subscribe to see Restore Vision’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Restore Vision at a glance
Restore Vision is a biotechnology company headquartered in Japan. It has raised at least $8.5M across the 2 funding rounds on record, 1 of them with a disclosed amount. Its most recent funding round, Series A, raised $8.5M in April 2026. Xcout tracks 9 named people at Restore Vision, including Yusaku Katada (CEO).
Restore Vision leadership
- Yusaku KatadaCEO
- Hikaru MiyazakiCOO
- Takahiro TadokoroCSO 研究開発本部長
- Teru Miyazaki代表取締役COO
- Hideki Kandorico-founder
- Toshihide Kuriharaco-founder
3 more named people on record for Restore Vision, with roles, board committees and tenure — see the full roster →
Restore Vision funding rounds
At least $8.5M raised across the 2 rounds on record (1 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $8.5M | 8 named | |
| Series A | Undisclosed | 8 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Restore Vision competitors
A few of Restore Vision's closest competitors — see the full list of competitors and alternatives →
Ray Therapeutics, Inc. is a privately held optogenetic gene therapy company headquartered in Berkeley, California. The company focuses on reimagining vision through innovative genetic treatments and novel therapeutic solutions.
Rejuvenate Bio, Inc. is a biotechnology company founded in 2019 and headquartered in San Diego, United States, specializing in innovative gene therapy applications.
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
SparingVision is a genomic and gene therapy medicines company translating pioneering science into vision-saving treatments, with US headquarters located in Boston, Massachusetts.
Beacon Therapeutics is a clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The company works to deliver advanced retinal gene therapies to patients experiencing blindness.
Coave Therapeutics is a clinical-stage biotechnology company headquartered in Paris, France. The company focuses on developing life-changing gene therapies targeting rare ocular and central nervous system diseases.
Get Restore Vision's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Restore Vision in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access